Literature DB >> 12676165

The renin-angiotensin and the kallikrein-kinin systems.

Duncan J Campbell1.   

Abstract

The renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS) each encompasses a large number of molecules, with several participating in both systems. The RAS generates a family of bioactive angiotensin peptides with varying biological activities. These include angiotensin-(1-8) (Ang II), angiotensin-(2-8) (Ang III), angiotensin-(3-8) (Ang IV), and angiotensin-(1-7) [Ang-(1-7)]. Ang II and Ang III act on type 1 (AT(1)) and type 2 (AT(2)) angiotensin receptors, whereas, Ang IV and Ang-(1-7) act on their own receptors. The KKS also generates a family of bioactive peptides with varying biological activities. These include hydroxylated and non-hydroxylated bradykinin and kallidin peptides and their carboxypeptidase metabolites des-Arg(9)-bradykinin and des-Arg(10)-kallidin. Whereas bradykinin and kallidin act mainly via the type 2 bradykinin (B(2)) receptor, des-Arg(9)-bradykinin and des-Arg(10)-kallidin act mainly via the type 1 bradykinin (B(1)) receptor. The AT(1) receptor forms heterodimers with the AT(2) and B(2) receptors and there is cross talk between the AT(1) and epidermal growth factor receptors. The B(2) receptor also interacts with angiotensin converting enzyme and nitric oxide synthase. Both angiotensin and kinin peptides are metabolised by many different peptidases that are important determinants of the activities of the RAS and KKS, and several of which participate in both systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676165     DOI: 10.1016/s1357-2725(02)00262-5

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  25 in total

1.  Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets.

Authors:  T Lau; P-O Carlsson; P S Leung
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

Review 2.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

3.  Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.

Authors:  Yong Li; Guang-Si Shen; Chen Yu; Guang-Fei Li; Jun-Kang Shen; You-Jia Xu; Jian-Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Surveying proteolytic processes in human cancer microenvironments by microdialysis and activity-based mass spectrometry.

Authors:  Markus Hardt; David K Lam; John C Dolan; Brian L Schmidt
Journal:  Proteomics Clin Appl       Date:  2011-12       Impact factor: 3.494

5.  Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase.

Authors:  S M Chajkowski; J Mallela; D E Watson; J Wang; C R McCurdy; J M Rimoldi; Z Shariat-Madar
Journal:  Biochem Biophys Res Commun       Date:  2010-12-16       Impact factor: 3.575

Review 6.  Renin-angiotensin system in the pathogenesis of liver fibrosis.

Authors:  Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

7.  Cathepsin K: a cysteine protease with unique kinin-degrading properties.

Authors:  Emmanuel Godat; Fabien Lecaille; Claire Desmazes; Sophie Duchêne; Enrico Weidauer; Paul Saftig; Dieter Brömme; Christophe Vandier; Gilles Lalmanach
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

8.  Genetic models provide unique insight into angiotensin and bradykinin peptides in the extravascular compartment of the heart in vivo.

Authors:  Duncan J Campbell; Hong D Xiao; Sebastien Fuchs; Kenneth E Bernstein
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-28       Impact factor: 2.557

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.